Liquid Biopsy and the Future of Early Cancer Detection
Dr. RP, MD — Board-Certified, Emergency Medicine & Critical Care Medicine — Founder, Analog Precision Medicine
Cancer kills most efficiently when it is found late. The five-year survival rate for colorectal cancer detected at Stage I exceeds 90%; detected at Stage IV, it falls below 15%. Pancreatic cancer diagnosed at Stage IA carries a five-year survival approaching 80%; diagnosed at Stage IV — its most common presentation — the figure drops below 3%. The clinical imperative for early detection is unambiguous. The challenge has always been biological: how do you find a tumor that has no symptoms, produces no detectable mass, and leaves no external trace?
Liquid biopsy — the detection of tumor-derived molecular signals in peripheral blood — represents the most consequential advance in cancer screening in a generation. This article reviews the biology of liquid biopsy, the major signal types in clinical use, the evidence base for current platforms, their validated limitations, and the trajectory of the field over the next five years.
The Biology of Liquid Biopsy
Circulating tumor DNA (ctDNA): Short fragments of cell-free DNA shed by tumor cells into the bloodstream. Tumor-derived cfDNA can be distinguished by somatic mutations, copy number alterations, or — most powerfully — tumor-specific DNA methylation patterns. ctDNA typically represents less than 1% of total cfDNA in early-stage cancers, necessitating high-sensitivity detection technologies.
Circulating tumor cells (CTCs): Intact cancer cells that have entered the bloodstream — as few as one CTC per 10⁹ normal blood cells. Cristofanilli et al.'s landmark 2004 NEJM paper established that CTC enumeration predicted progression-free and overall survival in metastatic breast cancer.[1] FDA-cleared CTC platforms (CellSearch) are used primarily in metastatic breast, prostate, and colorectal cancer monitoring.
Cell-free RNA (cfRNA): RNA transcripts shed by tumor cells into plasma. cfRNA provides information about gene expression patterns that DNA-based assays cannot; however, RNA is less stable than DNA, complicating pre-analytical handling.
Tumor-educated platelets (TEPs): Platelets that take up tumor-derived RNA during circulation through the tumor vasculature. TEP RNA profiles can discriminate patients with cancer from healthy controls and may provide tumor localization information.
Exosomes and extracellular vesicles: Membrane-bound particles released by tumor cells carrying a cargo of proteins, nucleic acids, and lipids. Exosome-based diagnostics remain largely in research phases but are a subject of active investigation.
Of these analytes, ctDNA — particularly methylation-based ctDNA detection — is currently the most clinically mature and has generated the most compelling clinical evidence for multi-cancer early detection (MCED).
Methylation-Based Multi-Cancer Early Detection: GRAIL Galleri
The GRAIL Galleri test is the most clinically validated MCED platform currently available. It is the platform included in the Nazaré tier at Analog Precision Medicine.
Platform Technology
Galleri uses genome-wide cell-free DNA methylation sequencing. DNA methylation — the addition of methyl groups to cytosine residues at CpG dinucleotides — is a stable epigenomic mark that is highly tissue- and cancer-type-specific. Machine learning algorithms trained on these patterns classify samples as cancer-signal detected or not detected, and when a signal is detected, attempt to localize the cancer to one of several tissue-of-origin categories.[2]
Clinical Validation: CCGA and PATHFINDER
The Circulating Cell-free Genome Atlas (CCGA) Substudy 3 (Klein et al., 2021) applied the methylation-based assay to 4,077 participants across 50+ cancer types:[3]
The PATHFINDER study (Schrag et al., 2023) prospectively evaluated Galleri in 6,621 adults aged 50+. A positive cancer signal was detected in 1.4% of participants; of those with completed diagnostic workup, cancer was confirmed in approximately 38%.[4]
The SYMPLIFY Study
In the UK, SYMPLIFY evaluated Galleri in 5,461 patients with symptoms suggestive of cancer referred to NHS rapid diagnostic services. Galleri sensitivity was 66.3% and specificity was 98.4%; tissue-of-origin prediction was accurate in 85.3% of cases.[5] Higher observed sensitivity than asymptomatic screening is consistent with higher tumor burden in symptomatic presentations.
Other Liquid Biopsy Platforms
CancerSEEK (Johns Hopkins)
CancerSEEK combines eight cancer-associated protein biomarkers with targeted ctDNA mutation analysis at 2,001 genomic positions. In 1,005 patients with non-metastatic cancers of eight types and 812 healthy controls, CancerSEEK achieved sensitivity of 69% and specificity of 99%.[6] Sensitivity varied by cancer type — ovarian 98%, pancreatic 72%, breast 33% — representing a distinct multi-analyte architecture from methylation-only platforms.
Minimal Residual Disease (MRD) Detection
A rapidly growing application of ctDNA is post-treatment MRD detection — identifying residual tumor DNA in patients following curative-intent surgery or chemotherapy. ctDNA-based MRD detection has been validated in colorectal cancer (DYNAMIC trial, CIRCULATE-Japan), breast cancer, and non-small-cell lung cancer, where its presence after treatment predicts relapse months to years before clinical or radiographic evidence appears.[7] This is the most clinically mature use of liquid biopsy in oncology.
Strengths and Limitations
Strengths
- —Screens 50+ cancer types including pancreatic, ovarian, and esophageal — cancers with no current population-level screening
- —High specificity (99.5%) minimizes false-positive-driven diagnostic workup
- —Tissue-of-origin guidance in 88–89% of cases focuses the diagnostic evaluation
- —Complements — does not replace — colonoscopy, mammography, PSA, and LDCT
Limitations
- —Stage I sensitivity remains ~17–28% — least sensitive at the stage where early detection matters most
- —Cancer type variation is substantial; performance for individual cancer types varies widely from published averages
- —No randomized trial evidence for mortality reduction yet — NHS-Galleri results expected late 2020s
- —~60% of positive results in PATHFINDER were ultimately not confirmed; false positives drive significant diagnostic burden
- —A negative result does not rule out cancer; existing single-cancer screening protocols remain essential
Conclusion
Liquid biopsy for multi-cancer early detection represents a genuine scientific advance — the first technology capable of screening for a broad spectrum of cancers, including many with no current screening modality, through a single blood draw. The current generation of platforms demonstrates high specificity and meaningful sensitivity at later stages, with Stage I performance that is real but limited.
“The test complements, rather than replaces, existing cancer screening. And it should always be accompanied by physician-led interpretation — because a cancer signal detected is the beginning of a clinical process, not the end of one.”
References
- 1.Cristofanilli M, Budd GT, Ellis MJ, et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med. 2004;351(8):781–791.
- 2.Liu MC, Oxnard GR, Klein EA, et al. Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA. Ann Oncol. 2020;31(6):745–759.
- 3.Klein EA, Richards D, Cohn A, et al. Clinical validation of a targeted methylation-based multi-cancer early detection test using an independent validation set. Ann Oncol. 2021;32(9):1167–1177.
- 4.Schrag D, Beer TM, McDonnell CH, et al. Blood-based tests for multicancer early detection (PATHFINDER): a prospective cohort study. Lancet. 2023;402(10409):1251–1260.
- 5.Krastins B, et al.; SYMPLIFY investigators. Multicancer early detection using a blood test in symptomatic individuals (SYMPLIFY): a large-scale, prospective cohort study. Lancet Oncol. 2023;24(7):733–743.
- 6.Lennon AM, Buchanan AH, Kinde I, et al. Feasibility of blood testing combined with PET-CT to screen for cancer and guide intervention. Science. 2020;369(6499):eabb9601.
- 7.Tie J, Wang Y, Tomasetti C, et al. Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer. Sci Transl Med. 2016;8(346):346ra92.
- 8.Wan JCM, Massie C, Garcia-Corbacho J, et al. Liquid biopsies come of age: towards implementation of circulating tumour DNA. Nat Rev Cancer. 2017;17(4):223–238.
- 9.Oxnard GR, Klein EA, Seiden MV. Association between cancer detection and survival outcomes in a multi-cancer early detection blood test. NPJ Precis Oncol. 2022;6(1):49.
Dr. RP, MD is dual board-certified in Emergency Medicine and Critical Care Medicine and is the founder of Analog Precision Medicine, a precision medicine practice in Southern California. This article is for educational purposes only and does not constitute medical advice or establish a physician-patient relationship.
← Back to Blog